Authors

Latest:

CD22-Directed CAR T-cell Therapy Elicits High CR Rates in LBCL After CD19 Relapse

CD22-directed CAR T-cell therapy generated high complete response rates and manageable safety in heavily pretreated patients with large B-cell lymphoma who relapsed following CD19-directed CAR T-cell therapy.

Lisa Barbarotta, MSN, AOCNS, APRN-BCÂ

Latest:

Nurse-Driven Website Empowers Nurses to Improve Patient Care

Improving communication, building relationships, coordinating activities among units, and engaging staff members are not only ways to create a more positive working environment, they are critical for maintaining patient safety.

Lisa Butterfield, PhD

Latest:

Lisa Butterfield on SITC Immune Biomarkers Task Force

Lisa Butterfield, PhD, professor of Medicine, Surgery and Immunology, director, University of Pittsburgh Cancer Institute Immunologic Monitoring and Cellular Products Laboratory, University of Pittsburgh, discusses the goals of the Society for Immunotherapy of Cancer (SITC) Immune Biomarkers Task Force during an interview at the SITC 31st Annual Meeting and Associated Programs.

Lisa Carey, MD

Latest:

Dr. Carey on the Clinical Implications of the FeDeriCa trial in HER2+ Breast Cancer

Lisa A. Carey, MD, FASCO, discusses the clinical implications of the phase 3 FeDeriCa trial in HER2-positive breast cancer.

Lisa Giulino Roth, MD

Latest:

Dr. Roth on Treating AYA Patients With Hodgkin Lymphoma

Lisa Giulino Roth, MD, assistant professor of Pediatrics in Medicine, Joan and Sanford I. Weill Department of Medicine , Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses treating adolescent and young adult patients with Hodgkin lymphoma.

Lisa H. Butterfield, PhD

Latest:

Potential Role of Immunotherapy in the Treatment of Patients With Sarcoma

Lisa H. Butterfield, PhD, professor of medicine, surgery, and immunology, director, University of Pittsburgh Immunologic Monitoring and Cellular Products Laboratory, University of Pittsburgh, president of the Society for Immunotherapy of Cancer, discusses the potential role for immunotherapy in the treatment of patients with sarcoma.

Lisa LaMotta

Latest:

5-FU Dose Optimization: Another Step Towards Personalizing Cancer Care

According to the Centers for Disease Control and Prevention, colorectal cancer is the second leading cancer killer in the United States, affecting both men and women.

Lisa M. Barroilhet, MD

Latest:

Dr Barroilhet on the Role of PARP Inhibitors in BRCA+ and HRD Ovarian Cancer

Lisa Barroilhet, MD, discusses the role of PARP inhibitors in patients with ovarian cancer.

Lisa M. Fucito, PhD

Latest:

Commentary: It's Time to Repackage the Fight Against Cigarettes

Twenty million people in the United States have died from cigarette smoking since 1965.

Lisa Marie Bernardo

Latest:

Why Practice Yoga?

Yoga is a lifestyle that promotes health. Health, through yoga practice, encompasses physical, mental and spiritual well-being.

Lisa Marie Bernardo, PhD, MPH, RN

Latest:

Yoga for Cancer Care

Mind-body methods are increasingly being used in cancer treatment, as patients are supplementing standard care with integrative therapies.

Lisa Miller

Latest:

Persistence Paved the Path of Discovery for an Immunotherapy Pioneer

Thomas F. Gajewski, MD, PhD, has made inroads in the field of cancer immunotherapy, most notably discovering the connections between the microbiome and clinical outcomes—findings that will enable the creation of microbiota-modulating interventions to improve outcomes in patients undergoing cancer treatments.

Lisa Newman, MD, MPH, FACS, FASCO

Latest:

Dr. Newman on Health Disparities in Breast Cancer

Lisa Newman, MD, MPH, FACS, FASCO, chief of Breast Surgery, Weill Cornell Medical Center and NewYork-Presbyterian, discusses health disparities among women with breast cancer.

Lisa Schulmeister MN, RN, FAAN

Latest:

Do Supplements Help Prevent Cancer?

A systematic review finds limited evidence of benefit.

Lisa Shomsky, BSN, MBA

Latest:

Merging Community Practices With an Academic Cancer Center

Consolidation of community oncology practices with hospital-based cancer centers is an accelerating trend that will affect future healthcare delivery models. This year, the Community Oncology Alliance reported hospital acquisitions and corporate mergers among 55% of 1338 community oncology practices surveyed, representing a 20% increase over the previous year's results.

Liza C. Villaruz, MD

Latest:

Dr. Villaruz on Updates From the CheckMate-227 Trial With Nivolumab/Ipilimumab in NSCLC

Liza C. Villaruz, MD, discusses updated data from the phase 3 CheckMate-227 trial examining nivolumab with or without ipilimumab in patients with non–small cell lung cancer.

Liza-Marie Johnson, MD, MPH, MSB

Latest:

Clinical Ethics 101: Practical Ethical Principles for Oncology Fellows

Education in medical ethics is required in medical school and residency programs, yet there is so much variability in the timing and delivery of this education and many house staff report inadequacies and gaps in their ethical training.

Lloyd B. Gayle, MD

Latest:

Dr. Gayle on Current Treatment Options in Breast Implant-Associated ALCL

Lloyd B. Gayle, MD, discusses current treatment options for patients who develop breast implant–associated anaplastic large cell lymphoma (ALCL).

Lloyd Damon, MD

Latest:

Dr. Damon on Optimal Treatment Regimens in AYA ALL

Lloyd Damon, MD, discusses optimal treatment regimens in adolescent/young adult acute lymphoblastic leukemia.

Loreen M. Brown, MSW

Latest:

NOW Initiative: Payer & Provider Collaborations in Oncology Benefits Management

Payers recognize the need to expand benefits management for oncology but struggle to find effective solutions amid the complexity of available therapies and skepticism from oncologists, who are facing their own set of economic pressures. The National Oncology Working Group (NOW) Initiative is trying to change the sometimes adversarial relationship between payers and oncologists through a collaborative model.